GlassScriptPhysician profile
Nicole M Moore
NPI 1700149101
$8,297.72
in general payments reported to CMS, 2019-2025
37 companies · $2,568 in 2025
The $2,568 reported for 2025 was more than what 96% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,161 · 2022: $1,310 · 2023: $1,558 · 2024: $1,701 · 2025: $2,568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,633 · Consulting Fee: $140 · Education: $54.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,633.01 |
| Consulting Fee | $140.00 |
| Education | $54.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,367.28 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,009.19 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $899.98 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $609.79 | 2021-2025 | Tremfya, Stelara, Simponi |
| Genzyme Corporation | $350.45 | 2022-2025 | |
| Qol Medical, LLC | $309.75 | 2021-2025 | Sucraid, Sucraid |
| Pfizer INC. | $307.47 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $271.16 | 2025 | Voquezna |
| Gilead Sciences, INC. | $267.94 | 2021-2025 | |
| Ardelyx, INC. | $267.07 | 2023-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $200.12 | 2022-2025 | Dupixent |
| Medtronic, INC. | $140.00 | 2023 | Interstim |
| Boston Scientific Corporation | $132.15 | 2022-2024 | Watchman Flx |
| Intercept Pharmaceuticals, INC. | $128.76 | 2021-2025 | Ocaliva |
| Merck Sharp & Dohme LLC | $118.53 | 2021-2023 | Dificid |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $103.43 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Aimmune Therapeutics, INC. | $79.24 | 2024-2025 | Zenpep, Vowst |
| Novo Nordisk INC | $75.55 | 2023-2024 | Wegovy |
| Ironwood Pharmaceuticals, INC | $65.92 | 2021-2023 | Linzess |
| Celgene Corporation | $65.64 | 2022-2024 | Zeposia |
| Amgen INC. | $63.96 | 2022-2023 | Amjevita, Avsola |
| Ipsen Biopharmaceuticals, INC | $60.49 | 2024-2025 | Iqirvo, Bylvay |
| Madrigal Pharmaceuticals | $60.31 | 2024-2025 | Rezdiffra, Resmetirom |
| Organon LLC | $59.76 | 2022-2024 | Renflexis |
| Tersera Therapeutics LLC | $44.55 | 2021-2023 | Xermelo |
| Daiichi Sankyo INC. | $36.22 | 2022-2025 | Injectafer |
| Alnylam Pharmaceuticals INC. | $31.83 | 2021-2023 | Givlaari |
| Fresenius Kabi USA, LLC | $30.57 | 2024 | Idacio |
| Mylan Institutional INC. | $20.00 | 2023 | Hulio |
| Ferring Pharmaceuticals INC. | $18.65 | 2024 | Rebyota |
| Nestle Healthcare Nutrition INC. | $18.64 | 2023 | |
| Vivus LLC | $16.26 | 2021 | |
| Lilly USA, LLC | $15.60 | 2024 | Omvoh |
| Csl Behring | $14.69 | 2022 | |
| Sandoz INC. | $13.30 | 2022 | |
| Evoke Pharma, INC. | $11.91 | 2021 | |
| Endogastric Solutions, INC | $11.56 | 2023 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.